

Socrates Herrera

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/647845/publications.pdf>

Version: 2024-02-01

19
papers

812
citations

516710

16
h-index

794594

19
g-index

22
all docs

22
docs citations

22
times ranked

810
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized clinical trial to assess the protective efficacy of a Plasmodium vivax CS synthetic vaccine. Nature Communications, 2022, 13, 1603.	12.8	9
2	Individualized Transcriptional Resolution of Complicated Malaria in a Colombian Study. Journal of Personalized Medicine, 2018, 8, 29.	2.5	2
3	Complicated malaria in children and adults from three settings of the Colombian Pacific Coast: A prospective study. PLoS ONE, 2017, 12, e0185435.	2.5	24
4	Clinical and epidemiological aspects of complicated malaria in Colombia, 2007â€“2013. Malaria Journal, 2016, 15, 269.	2.3	29
5	Protective Efficacy of Plasmodium vivax Radiation-Attenuated Sporozoites in Colombian Volunteers: A Randomized Controlled Trial. PLoS Neglected Tropical Diseases, 2016, 10, e0005070.	3.0	50
6	High prevalence of sub-microscopic infections in Colombia. Malaria Journal, 2015, 14, 201.	2.3	42
7	Clinical profile of Plasmodium falciparum and Plasmodium vivax infections in low and unstable malaria transmission settings of Colombia. Malaria Journal, 2015, 14, 154.	2.3	60
8	Transcription Profiling of Malaria-Naïve and Semi-immune Colombian Volunteers in a Plasmodium vivax Sporozoite Challenge. PLoS Neglected Tropical Diseases, 2015, 9, e0003978.	3.0	32
9	Plasmodium vivax Sporozoite Challenge in Malaria-Naïve and Semi-Immune Colombian Volunteers. PLoS ONE, 2014, 9, e99754.	2.5	52
10	Malaria Vaccine Development Using Synthetic Peptides as a Technical Platform. Advances in Immunology, 2012, 114, 107-149.	2.2	14
11	Antibody-Mediated and Cellular Immune Responses Induced in Naive Volunteers by Vaccination with Long Synthetic Peptides Derived from the Plasmodium vivax Circumsporozoite Protein. American Journal of Tropical Medicine and Hygiene, 2011, 84, 35-42.	1.4	21
12	Consistent Safety and Infectivity in Sporozoite Challenge Model of Plasmodium vivax in Malaria-Naive Human Volunteers. American Journal of Tropical Medicine and Hygiene, 2011, 84, 4-11.	1.4	60
13	Preclinical Vaccine Study of Plasmodium vivax Circumsporozoite Protein Derived-Synthetic Polypeptides Formulated in Montanide ISA 720 and Montanide ISA 51 Adjuvants. American Journal of Tropical Medicine and Hygiene, 2011, 84, 21-27.	1.4	21
14	Phase I Safety and Immunogenicity Trial of Plasmodium vivax CS Derived Long Synthetic Peptides Adjuvanted with Montanide ISA 720 or Montanide ISA 51. American Journal of Tropical Medicine and Hygiene, 2011, 84, 12-20.	1.4	65
15	Current status of Plasmodium vivax vaccine. Hum Vaccin, 2010, 6, 124-132.	2.4	86
16	Successful Sporozoite Challenge Model in Human Volunteers with Plasmodium vivax Strain Derived from Human Donors. American Journal of Tropical Medicine and Hygiene, 2009, 81, 740-746.	1.4	55
17	ANTIGENICITY, IMMUNOGENICITY, AND PROTECTIVE EFFICACY OF PLASMODIUM VIVAX MSP1 PV200L: A POTENTIAL MALARIA VACCINE SUBUNIT. American Journal of Tropical Medicine and Hygiene, 2005, 73, 16-24.	1.4	67
18	SAFETY AND ELICITATION OF HUMORAL AND CELLULAR RESPONSES IN COLOMBIAN MALARIA-NAIVE VOLUNTEERS BY A PLASMODIUM VIVAX CIRCUMSPOROZOITE PROTEINâ€“DERIVED SYNTHETIC VACCINE. American Journal of Tropical Medicine and Hygiene, 2005, 73, 3-9.	1.4	74

#	ARTICLE	IF	CITATIONS
19	Use of long synthetic peptides to study the antigenicity and immunogenicity of the Plasmodium vivax circumsporozoite protein. International Journal for Parasitology, 2004, 34, 1535-1546.	3.1	49